# A Study To Assess Distribution Of RO7248824 In The Central Nervous System Following Single Intrathecal Doses Of [89zr] Labeled RO7248824 In Healthy Male Participants

> **NCT04863794** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 21 (actual)

## Conditions studied

- Angelman Syndrome

## Interventions

- **DRUG:** RO7248824

## Key facts

- **NCT ID:** NCT04863794
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-29
- **Primary completion:** 2022-08-01
- **Final completion:** 2022-08-01
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2022-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04863794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04863794, "A Study To Assess Distribution Of RO7248824 In The Central Nervous System Following Single Intrathecal Doses Of [89zr] Labeled RO7248824 In Healthy Male Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04863794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*